Company profile: AskBio
1.1 - Company Overview
Company description
- Provider of AAV-based gene therapies for genetic disorders and rare diseases, offering proprietary AAV technology, manufacturing capabilities, and in-house clinical programs. Pipeline includes AB-1002 for advanced heart failure (GenePHIT Phase 2), ACT-101 for late-onset Pompe disease, and NAN-101 for congestive heart failure, plus research on AAV immune responses and episome configuration.
Products and services
- ACT-101 for Late-Onset Pompe Disease: Intravenously infused, liver-directed AAV gene therapy delivering a functional GAA gene to the liver to restore GAA production and potentially eliminate the need for enzyme replacement therapy
- AB-1002: Heart-targeted AAV gene therapy delivering a functioning copy of the gene to the heart to treat advanced heart failure
- NAN-101 for Congestive Heart Failure: Mechanism-specific AAV therapy targeting protein phosphatase inhibitor 1 (I-1c) to improve heart function in patients with congestive heart failure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AskBio
Lundbeck
HQ: Denmark
Website
- Description: Provider of pharmaceuticals for psychiatric and neurological disorders, engaged globally in the research, development, production, marketing, and sale of these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lundbeck company profile →
Naurex
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for depression and other CNS disorders, based on a novel mechanism to modulate the N-methyl-D-aspartic acid receptor (NMDAR); developing novel chemical drug classes called glycine-site functional partial agonists (GFPAs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Naurex company profile →
Neurelis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies addressing unmet medical needs, including VALTOCO, a prescription nasal spray for short-term treatment of seizure clusters in patients aged 6 and older; and pipeline programs NRL-1004 for acute agitation using proprietary Intravail delivery technology, and NRL-1049 for cerebral cavernous malformations, potentially the first FDA-approved treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurelis company profile →
Vaxxinity
HQ: United States
Website
- Description: Provider of synthetic peptide vaccine technologies and Active Immunotherapy Medicines (AIMs) that stimulate antibody production to address chronic and infectious diseases, including UB-311 for mild Alzheimer’s (targets amyloid beta), UB-312 for Parkinson’s (targets alpha-synuclein), VXX-401 anti-PCSK9 to reduce LDL-C for heart disease, and UB-612, a multitope protein-peptide vaccine against SARS-CoV-2 variants like Omicron.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxxinity company profile →
Envoy Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envoy Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AskBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AskBio
2.2 - Growth funds investing in similar companies to AskBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AskBio
4.2 - Public trading comparable groups for AskBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →